On Nov 05, major Wall Street analysts update their ratings for $Glaukos (GKOS.US)$, with price targets ranging from $140 to $149.
J.P. Morgan analyst Allen Gong maintains with a buy rating, and adjusts the target price from $130 to $145.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and maintains the target price at $145.
Needham analyst David Saxon maintains with a buy rating, and adjusts the target price from $137 to $149.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $139 to $140.
Piper Sandler analyst Matthew O'Brien maintains with a buy rating, and maintains the target price at $140.
Furthermore, according to the comprehensive report, the opinions of $Glaukos (GKOS.US)$'s main analysts recently are as follows:
Glaukos' Q3 outcomes surpassed consensus forecasts with iDose generating $8.8M in conjunction with a 12.3% increase in the iStent infinite and the broader iStent range within the U.S. market. Additionally, the company's Glaucoma business is expanding steadily, achieving growth of over 20% internationally.
Glaukos' third quarter sales surpassed consensus forecasts, fueled by the performance of iDose and OUS MIGS. Following this, management increased their sales guidance by $5 million at the midpoint, corresponding to the scale of the outperformance. There is positive momentum anticipated for iDose continuing into the fourth quarter and towards 2025.
Here are the latest investment ratings and price targets for $Glaukos (GKOS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
